WO2002054070A1 - Puces proteiques, leur procede de production, leur systeme de detection et le procede de mise en route du systeme de detection - Google Patents

Puces proteiques, leur procede de production, leur systeme de detection et le procede de mise en route du systeme de detection Download PDF

Info

Publication number
WO2002054070A1
WO2002054070A1 PCT/CN2001/001294 CN0101294W WO02054070A1 WO 2002054070 A1 WO2002054070 A1 WO 2002054070A1 CN 0101294 W CN0101294 W CN 0101294W WO 02054070 A1 WO02054070 A1 WO 02054070A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
chip
protein chip
proteins
detection system
Prior art date
Application number
PCT/CN2001/001294
Other languages
English (en)
French (fr)
Inventor
Gengxi Hu
Original Assignee
Shanghai Health Digit Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Health Digit Limited filed Critical Shanghai Health Digit Limited
Priority to CA002428428A priority Critical patent/CA2428428A1/en
Priority to EP01982082A priority patent/EP1348961A4/en
Priority to JP2002554717A priority patent/JP2004516489A/ja
Publication of WO2002054070A1 publication Critical patent/WO2002054070A1/zh
Priority to US10/464,127 priority patent/US20030228631A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures

Definitions

  • the invention relates to a protein chip for multi-parameter parallel detection, a preparation method and a use method thereof. Background technique
  • Biochip technology is an emerging biotechnology that emerged in the mid-1990s. Because it can perform parallel analysis of multiple types of information in one reaction, it has attracted the attention of many researchers and has been rapidly applied in many biological fields.
  • Biochip technology is classified according to the detection object, and is mainly divided into two types: gene chip and protein chip. Since the gene chip plays an important role in the research work of the Human Genome Project, this technology has been greatly developed in just a few years. At present, the human genome project is about to be completed, and the research focus of biological sciences is about to shift from genomic research to proteomic research. As a result, many technology-leading laboratories have shifted their research focus to functional studies of known genes in the human genome.
  • One of the technical problems to be solved by the present invention is to provide a protein chip for parallel detection of multiple indicators
  • the second technical problem to be solved by the present invention is to provide a method for preparing the above-mentioned protein chip
  • the third technical problem to be solved by the present invention is to provide the above-mentioned protein chip detection system
  • the fourth technical problem to be solved by the present invention is to provide a method for using the protein chip detection system.
  • the preparation principle of the protein chip for multi-parameter parallel detection according to the invention is as follows:
  • the protein can be bound to the solid phase carrier by means of physical adsorption or covalent bonding, a variety of proteins can be immobilized on the solid phase carrier at a high density using a chip automatic spotting system;
  • the unfixed protein region on the solid phase carrier can randomly adsorb proteins and other small molecules, which affects the detection accuracy of the protein chip. Therefore, a specific blocking solution is required to seal off the non-spotted parts of the solid phase carrier;
  • the manufacturing method of the protein chip for parallel detection of multi-finger salamander according to the present invention is as follows:
  • the protein chip for multi-indicator parallel detection has the following characteristics: 1)
  • the solid support is an inorganic substrate or an organic compound substrate, and the inorganic substrate includes a semiconductor Silicon wafers, glass wafers, microporous silicon wafers, microporous glass, etc. are preferred glass sheets; organic substrates include cellulose acetate films, nitrocellulose films, nylon films, polypropylene films, etc., and nitrocellulose films are preferred.
  • Proteins can be antigens, antibodies, receptors, ligands, etc., and further refer to proteins that can specifically bind to disease marker proteins in the body, especially tumor marker proteins.
  • the receptors are biological macromolecules that can recognize and bind biologically active molecules (drugs, toxins, neurotransmitters and hormones, antigens and cell adhesion molecules, etc.) on or in the cell membrane. They can pass information generated by biologically active molecules to effectors, thereby causing corresponding biological effects. Most of these biological macromolecules are proteins, and some are glycolipids.
  • Ligands are biologically active molecules that can specifically bind to receptors (ie drugs, toxins, neurotransmitters and hormones, antigens and cell adhesion molecules, etc.).
  • the receptors and ligands referred to in the present invention are proteins.
  • Coating solution CBS (NaHC0 3 -Na 2 C0 3 ) with a pH of 9.0-10.0 (optimal 9.6).
  • the function of the coating solution is to provide a certain pH range, so that the chemical reaction or physical adsorption reaction between the protein and the solid support can be better combined in the liquid phase.
  • the blocking solution contains 0.1-0.5% Tween 20, 0.02-0.3% tyrosine, 1- 93 ⁇ 4 sucrose, 1-9% BSA, 0.1% Prolin TBS (0.7-0.9% NaCl. 1. 0-1.5% Tis), the best is TBS containing 0.2 Tween 20, 0.1% tyrosine, 4% sucrose, 5% BSA, 0.5% proclin.
  • TBS containing 0.2 Tween 20, 0.1% tyrosine, 4% sucrose, 5% BSA, 0.5% proclin.
  • Tyrosine and BSA have a blocking effect, proclin can be preserved, sucrose is an inert substance and can block the air, and BSA and sucrose can be used as materials to support the frame structure.
  • the blocking solution prevents the other parts of the solid phase carrier from binding to proteins, thereby ensuring the accuracy of the experimental data.
  • the present invention also tried several other blocking solutions: one is TTBS-0.1% (V / V) Tween20 TBS, 10% TBS with 4 milk points, TTBS with 0.2% protein. References are: Bejurrum and Schater-Nielsen, 1986; Gillespie and Hudspeth>1991; Harlow and Lane>1988; Schneppenheim et al., 1991. The other is 5% (W / V) skimmed milk powder in PBS. References are: Molecular Cloning: A Laboratory Manual (2nd ed): J. sambrook, EFFritsch T. Maniatis.
  • the object of the present invention for detection is various body fluids, so the materials are convenient to obtain and the stimulation to the patient is small.
  • the detection principle of the protein chip provided by the present invention is: different proteins (abbreviated as B) produced on the protein chip can be specifically combined with corresponding proteins (abbreviated as A) contained in body fluids, tissues, cells, etc.
  • the bound protein complex (BA) can bind another specific binding protein (C) for the corresponding protein (A).
  • C has been labeled with peroxidase (C-labeled), so it forms a quadruple Complex (BAC-labeled).
  • This peroxidase can catalyze a chemiluminescence reaction, and the intensity of the light signal generated can be detected only quantitatively by specific biochip detection. Therefore, the content of protein (A) contained in the body can be detected by the intensity of the detected light signal.
  • the protein chip detection system for multi-index parallel detection according to the present invention includes:
  • a protein chip for parallel detection of multiple indicators (1) A protein chip for parallel detection of multiple indicators
  • the method of using the protein chip detection system for multi-parameter parallel detection according to the present invention is as follows:
  • the protein chip detection system for multi-parameter parallel detection has the following characteristics: Unless otherwise specified, the following concentration units are W / V.
  • a multi-protein mixed solution is a mixed solution of a plurality of peroxidase-labeled proteins that can specifically bind to a protein detected in a body fluid in a stable solution.
  • the marker may be peroxidase, and further peroxidase is horseradish peroxidase.
  • the washing solution contains 0.7-0.
  • the preferred formula is 0.9% NaCl, 1.21% Tris, 0.1% Tween 20, and the pH is 7.50.
  • the diluent contains (7-0.93 ⁇ 4NaCl, 1.0-1.5% Tris, 0.05-0.2% Tween 20, 0.05-0.2% road acid. Among them, the preferred S-square is 0.93 ⁇ 4NaCl. 1.21% Tris , 0.1% Tween 20, 0.1% tyrosine.
  • Stable solution formula is 70-80% A solution (V / V) + 5- 20% ethylene glycol (V / V) + 1-9% sucrose (W / V) + 0. ll proclin (V / V ) + 0.05-0.5% EDTA.2Na (A solution contains 40-60% 0.05 M PBS (pH 7.2) and 40-60% fetal calf serum).
  • Optimal formula 80% A solution (V / V) + 19% ethylene glycol (V / V) + 3% sucrose (W / V) + 0.5% proclin (V / V) + 0.% EDTA-2Na, (A solution contains 60% 0.05 M PBS (pH 7.2) and 40% fetal calf serum).
  • a series of standards refers to a mixture of a variety of different concentrations of the test protein. It is prepared by mixing the test protein (which should be detected in body fluids) corresponding to each protein on the protein chip. This standard can be used with A variety of proteins on the protein chip are bound, and after the reaction steps described in the above use method, each protein position on the protein chip will be detected with a certain light signal intensity. If a standard in the detection system is used as a control, there is a significant signal difference between the test sample and the standard, indicating that the finger is positive. Reconstitute the standard with deionized water before use.
  • compositions for generating chemiluminescence reactions There are two types of chemiluminescence reactions: ordinary chemiluminescence and enhanced Chenmiluminescence.
  • the present invention uses an enhanced chemiluminescence reaction.
  • the reagents involved in the reaction are Luminol (5-amino-2, 3-dihydro-1, 4-phthalazinedione Sodium Salt), H 2 0 2 (hydrogen peroxide), Enhancer (Eosin-eosin or PIP-p-iodophenol ), Peroxide (such as horseradish peroxidase HRP), were purchased from Sigma.
  • a significant advantage of the protein chip for parallel detection of multiple indicators according to the present invention is the simultaneous introduction of multiple disease indicators, which greatly increases the accuracy of detection.
  • Most of the existing disease indicators are non-specific indicators. Not only does the content of multiple markers increase significantly in the same disease at the same time, but the content of the same marker also increases in multiple diseases. This situation causes disease diagnosis. Difficulty leads to misdiagnosis.
  • the existing disease marker proteins are non-specific indicators, and even the recognized primary liver cancer indicator AFP (alpha-fetoprotein)
  • AFP alpha-fetoprotein
  • the detection rate of liver cancer is only about 70%, and AFP is also significantly increased in the serum of some patients with testicular cancer, teratoma, gastric cancer, and pancreatic cancer. Therefore, the necessity of joint detection of multiple species is proposed.
  • the detection rate of CA19-9 is about 60%, plus CA125, CA50 and DU-PAN-, the detection rate can be mentioned above 90%.
  • Another example is lung cancer: CEA alone has a higher specificity for the diagnosis of lung cancer, but if NSE, sialic acid, CEA, and SCC are added, the specificity is higher.
  • Another advantage of the protein chip for multi-parameter parallel detection according to the present invention is high sensitivity.
  • the use of chemiluminescence reaction and enhanced luminescence reaction enables the protein chip to detect target proteins with only lpg per ml of body fluid, which makes some Protein fingers with high specificity but low content in body fluids can be used for clinical detection, thereby expanding the selection range of clinical detection indicators.
  • protein chips can provide efficient, convenient, and accurate clinical detection methods for modern medical diagnostics. It is of great significance for the diagnosis of difficult diseases and the early diagnosis and timely treatment of malignant diseases such as tumors. Since proteins are closer to the material level of life than genes, protein chips have more direct application prospects in life science related fields such as disease diagnosis and treatment, new drug development, and exploring molecular mechanisms of diseases.
  • the compliance status of the protein chip detection system of the present invention is:
  • Sensitivity true positive / (true positive + false negative)> 80%;
  • the lower limit of detection is 10-12 g / L for serum samples.
  • Stability Stable for 2 years at 4 ° C; Stable for 1 week at 37 ° C.
  • FIG. 1 is a schematic diagram of the results of a standard blood sample detected by the protein chip of the present invention
  • FIG. 2 is a schematic diagram of blood sample results of liver cancer patients detected by the protein chip of the present invention. The best way to implement the invention
  • Example 1 Preparation of a protein chip
  • Solid support nitrocellulose membrane.
  • Proteins used on solid-phase carriers Monoclonal antibodies to detect tumor marker proteins, the amount used is 5 ng, and the spot density is 25 dots / 0.36 cm 2 .
  • Spots are Al, A2—CA153 antibody, A3, A4—CA19-9 antibody, A5—negative control, Bl, B2—CA125 antibody, B3, C4—AFF antibody, CI, C2—CA125 antibody, C3, B4— beta-HCG antibody, B5, C5—CA19-5 antibody, Dl, D2—PSA antibody, D3, E4—CEA antibody, El, E2—PSA antibody, E3, D4—CA15-3 antibody, D5, E5—CA549 antibody .
  • Antibodies were purchased from Fitzgerald, CanAg.
  • AFP alpha-fetoprotein
  • CEA carcinoembryonic antigen
  • PSA prostate specific antigen
  • betaHCG human chorionic gonadotropin beta subunit
  • CA carbohydrate antigens
  • Coating solution CBS (NaHC0 3 -Na 2 C0 3 ), pH 9.6.
  • Blocking solution 0.9 NaCl. 1.21% Tris, 0.2% Tween 20. 0.1% tyrosine, 4% sucrose, 5% BSA, 0.5% proclin.
  • Example 2 Detection of protein A blood sample of a normal human (see FIG. 1) and a blood sample of a liver cancer patient (see FIG. 2) are compared using the protein chip of the present invention.
  • the advantages and application prospects of the invention are very obvious.
  • the use of the protein chip of the present invention greatly improves the accuracy of detection, and has the advantages of high reliability and high detection sensitivity, and can be widely used in molecular biology, biomedicine, and human proteome research, especially for clinical diagnosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Description

蛋白芯片和其制备方法以及使用该蛋白芯片的
检测系统和使用该检测系统的方法 技术领域
本发明涉及一种用于多指标并行检测的蛋白芯片及其制备方法和 使用方法。 背景技术
生物芯片技术是九十年代中期兴起的一项新兴生物技术, 因其可 在一次反应中进行多种信息的平行分析, 而受到众多研究者的瞩目 , 迅速在诸多生物学领域得到应用 。
生物芯片技术按检測对象分类, 主要分为基因芯片和蛋白芯片 两 类。 由于基因芯片在人类基因組计划的研究工作中起重要作用, 因而 此技术在短短几年内得到了长足的发展。 目前, 人类基因組计划即将 完成, 生物科学的研究重心即将从基因组研究转向蛋白质組研究。 因 此, 许多技术领先的实验室已将研究重点转移至对人类基因组中已知 基因的功能研究上。
目前可用于同时研究多种蛋白质的方法多用 cDNA芯片, 由于蛋白 质与蛋白质之间的特异作用主要是抗原 -抗体反应或受体的反应,即构 象的特异性, 无序列特异性, 因此用 DNA芯片模式检测蛋白质有其局 限性, 更好的研究蛋白质与蛋白质功能的手段是蛋白芯片技术。 它通 过固定于支持介质上的多种蛋白质抅成的微阵列, 直接检测有特定功 能的标志性蛋白。 由于蛋白芯片的研制难度较大, 目前对蛋白芯片的 研究和应用尚很少。
现有的检测尿液、 血清及其它体液的方法, 如 ELISA、 放射性同 位素标记、 金栎、 荧光、 化学发光、 时间分辨荧光等, 大多是单指标 检测, 信息量少, 而且均具有局限性, 如标记步骤复杂、 仅器和试剂 昂贵、 操作烦琐、 灵敏度低、 易污染等。 发明的公开
本发明需要解决的技术问题之一是提供一种用于多指标并行检测 的蛋白芯片 ;
本发明需要解决的技术问题之二是提供上述蛋白芯片的制备方 法;
本发明需要解决的技术问题之三是提供上述蛋白芯片的检测系 统;
本发明需要解决的技术问题之四是提供上述蛋白芯片的检测系统 的使用方法。
本发明所述用于多指标并行检测的蛋白芯片的制备原理如下:
1 )由于蛋白质可以通过物理吸附或共价结合的方式结合到固相载 体上, 因此利用芯片 自动点样系统, 可将多种蛋白质以一定的排列次 序高密度地固定在固相载体上;
2)固相载体上未固定蛋白的区域可以随机地吸附蛋白质及其它小 分子, 从而影响蛋白芯片的检测准确度, 因此需要用特定的封闭液将 固相载体的非点样部位封闭;
3) 为了长期保持蛋白活性, 封闭后的固相载体需要低温保存。 本发明所述用于多指柘并行检测的蛋白芯片的制作方法如下:
1 )将蛋白芯片上所要点制的蛋白质以一定浓度溶于包被液中;
2)用芯片 自动点样系统将这些蛋白质点制在固相载体上, 点样密 度在 25-200点 /cm2 , 点样量 0 . 1-10 ng/点;
3 )放置过夜;
4)用封闭液将蛋白芯片封闭冻干处理, 储存于 4 (:。
本发明所述用于多指标并行检测的蛋白芯片有如下几点特征: 1 ) 固相载体是无机片基或有机化合物片基, 无机片基包括半导体 硅片 、 玻璃片 、 微孔硅片 、 微孔玻璃等, 首选玻璃片 ; 有机片基包括 醋酸纤維素膜、 硝酸纤维素膜, 尼龙膜, 聚丙烯膜等, 首选硝酸纤维 素膜。
2) 蛋白质可以是抗原、 抗体、 受体、 配体等, 进一步指能与体内 疾病性标志蛋白特异结合的蛋白质, 尤其是肿瘤标志性蛋白质 。 其中 的受体是细胞膜上或细胞内能识别生物活性分子(药物、毒素、神经递 质和激素、抗原和细胞粘附分子等)并与之相结合的生物大分子。它们 能将生物活性分子产生的信息传递到效应器, 从而引起相应的生物效 应。 这些生物大分子多数是蛋白质, 个别的是糖脂。 配体是能与受体 特异结合的生物活性分子(即药物、毒素、神经递质和激素、抗原和细 胞粘附分子等)。 本发明中指的受体和配体是蛋白质 。
3 )为了使我们的芯片上所点的多种蛋白质在发生一系列反应后产 生的化学发光信号能在相邻两个数量級上(最强点 /最弱点 <100) ,以便 于同一检測仅器的检测, 我们事先调节了芯片上蛋白质的浓度。
4) 包被液: pH为 9.0- 10.0(最佳 9.6)的 CBS (NaHC03-Na2C03) 。 包被液的作用是提供一定的 PH范围,使得蛋白质和固相载体之间 的化学反应或物理吸附反应在液相能更好地结合。
5) 封闭液含 0. 1-0.5%Tween 20、 0.02- 0.3%酪氨酸、 1 - 9¾蔗糖、 1-9%BSA、 0.卜 l%proclin的 TBS (0.7-0.9%NaCl . 1 .0-1 .5%Tis) , 最 佳为含 0.2 Tween 20、 0. 1%酪氨酸、 4%蔗糖、 5%BSA、 0.5%proclin 的 TBS。优点是: 酪氨酸和 BSA有封闭作用 , proclin可以防腐, 蔗糖 是惰性物质, 能隔绝空气, BSA 和蔗糖可作为支持框架结构的物质 。 封闭液的作用使固相载体的其它部位不能结合蛋白质, 从而保证实验 数据的准确性。
本 发 明 还 尝 试 了 其 它 几种 封 闭 液 : 一 种 为 TTBS― 0. 1%(V/V)Tween20的 TBS , 含 10% 月§奶 4分的 TBS , 含 0 · 2% 蛋白的 TTBS。参照的文献有: Bejurrum and Schater-Nielsen , 1986; Gillespie and Hudspeth > 1991; Harlow and Lane > 1988; Schneppenheim et al.,1991 。 另一种为 5%(W/V)脱脂奶粉的 PBS。 参照的文献为 : Molecular Cloning: A Laboratory Manual (2nd ed): J . sambrook, E.F.Fritsch T . Maniatis。
通过对结果的信噪比的分析, 证明本发明提供的封闭液明显优于 上述二种。
6) 本发明所用于检测的对象是各种体液, 因此材料获取方便, 对 病人刺激小。
以上浓度单位除非特指均为 W/V。
本发明所提供的蛋白芯片的检测原理是: 蛋白芯片上所点制的不 同蛋白质 (简称为 B) 可特异性地与体液、 组织、 细胞等所含的相应 蛋白质 (简称为 A) 相结合, 结合后的蛋白复合体 (B-A) 又可结合相 应蛋白质 (A) 的另一特异性可结合蛋白 (简称为 C) , C 已被标记过 氧化物酶(简称 C-labeled) ,所以形成四联复合物(B-A-C- labeled)。 此过氧化物酶可催化一个化学发光反应, 产生的光信号强度可被特定 的生物芯片检测仅定量检测。 所以, 可通过被检测的光信号强度来检 测机体内所含蛋白质 (A) 的含量。
本发明所述用于多指标并行检测的蛋白芯片检测系统包括:
(1)一种用于多指标并行检测的蛋白芯片 ;
(2)—种标记过氧化物酶的多蛋白质混合液;
(3)—种用于稀释被测体液的稀释液;
(4)一种由产生并增强化学发光反应的化合物組成的化学组合物;
(5)—种蛋白芯片的洗涤液;
(6)—系列被检蛋白质的标准品。
本发明所述用于多指标并行检测的蛋白芯片检测系统的使用方法 如下:
1) 用稀释液将待测的体液上清液稀释, 一般稀释 5-20倍; 2) 吸取体液上清液, 按照每平方厘米蛋白芯片约 500ul的体积滴 加到蛋白芯片表面, 在 200-300转 /分和 20-37 C下振摇 20-30分钟, 使体液中的特定蛋白质(A)与固定于蛋白质芯片上的其特异性结合蛋 白(B)起反应, 形成稳定复合物 B -A ;
3) 吸干反应液, 将蛋白质芯片放在洗涤液中在 20-37 C下振摇 洗涤 3-6分钟, 重复多次;
4)吸取已标记过氧化物酶的多蛋白质混合液, 按照每平方厘米蛋 白质芯片约 500 μΐ的体积滴加到蛋白质芯片表面, 在 200-300 转 /分 和 20-37 C下振摇 20-30分钟, 使稳定复合物 Β-Α中的 Β部分与多蛋 白质混合液中对应椋记过氧化物酶的特异性结合蛋白( C-labelled )起 反应, 形成稳定的三聚物 B-A-C- labelled;
5) 吸干反应液, 将蛋白芯片放在洗涤液中在 20 - 37 C下振摇洗 涤 3-6分钟, 重复多次;
6) 在晾千后的芯片表面滴加产生化学发光反应的化学组合物 ( 100 ul/cm2), 在 20-37 C下催化反应 3-5分钟;
7) 取出芯片 , 用特定的生物芯片检测仅检测光信号。
本发明所述用于多指标并行检测的蛋白芯片检测系统有如下几点 特征: 以下浓度单位除非特指均为 W/V。
1 )多蛋白混合液是可与在体液中被检测到的蛋白质特异性结合的 多种标记过氧化物酶的蛋白质在稳定溶液中的混合液。
2)标记物可以是过氧化物酶, 进一步过氧化物酶是辣根过氧化物 醉。
3) 洗涤液内含 0.7-0.輩 aCl, 1 .0-1 .5% Tris , 0.05-0.2%Tween 20, pH值在 6.0至 9.0之间。其中优选配方为 0.9%NaCl , 1 .21% Tris , 0. 1%Tween 20, pH值为 7.50。
4) 稀释液内含( 7-0.9¾NaCl, 1 .0-1 .5% Tris , 0.05-0.2%Tween 20, 0.05—0.2%路氛酸。 其中优选 S己方为 0.9¾NaCl . 1 .21% Tris , 0.1%Tween 20, 0.1%酪氨酸。
5) 稳定溶液配方为 70-80% A溶液 (V/V) +5- 20%乙二醇 (V/V) + 1-9%蔗糖 (W/V)+0. l-l proclin(V/V)+0.05-0.5%EDTA.2Na( A 溶液包 含 40-60% 0.05 M的 PBS(pH7.2)和 40- 60%胎牛血清)。 最佳配方: 80% A 溶 液 ( V/V ) +19% 乙 二 醇 ( V/V ) +3% 蔗 糖 (W/V)+0.5% proclin(V/V)+0. %EDTA-2Na , (Α溶液包含 60% 0.05 M的 PBS(pH7.2) 和 40%胎牛血清)。
6) 一系列标准品指多种不同浓度的被检蛋白质的混合物, 由蛋白 芯片上的每种蛋白质对应结合的被检测蛋白质(应在体液中被检测到) 混合配制成, 此标准品可与蛋白芯片上的多种蛋白结合, 经过以上使 用方法所述的反应步骤, 使蛋白芯片上的每个蛋白位置均会被检测到 一定的光信号强度。 如用检测系统中标准品作对照, 被检样品相对于 标准品有显著性信号差异, 表明该指柘呈阳性。 标准品用前用去离子 水复溶。
7) 产生化学发光反应的組合物: 化学发光反应有 2种类型: 普通 化学发光反应(Chemiluminescence)和增强的化学发光反应(Enhanced Chenmiluminescence)。本发明用的是增强的化学发光反应。反应涉及 的试剂是 Luminol ( 5-amino-2 , 3-dihydro - 1 , 4-phthalazinedione Sodium Salt), H202(过氧化氢), 增强子 Enhancer (Eosin-曙红或 PIP- 对碘苯酚), 过氧化物晦 (如辣根过氧化物酶 HRP) , 均购自 Sigma公 司。
本发明所述用于多指标并行检测的蛋白芯片的一个显著优点是同 时引入多种疾病指标, 使得检测的准确性大大增加。 现有的疾病指标 绝大多数是非特异性指椋, 不仅多个标志物含量在同一疾病同时显著 升高, 而且同一标志物含量在多种疾病皆会升高, 这种情况造成疾病 诊断上的困难, 导致误诊。 对肿瘤的检测来说, 现有的疾病标志性蛋 白均是非特异性指标, 就连公认的原发性肝癌指标 AFP (甲胎蛋白)对 肝癌的检出率只有 70%左右, 并且 AFP在某些睾丸癌、 畸胎瘤、 胃癌、 胰腺癌等患者血清中也有明显增高。 因此提出了多种柘志物联合检测 的必要性。 如胰腺癌: CA19-9 检出率约 60% , 加上 CA125、 CA50 及 DU-PAN-则可把检出率提到 90%以上。 再如肺癌: 单用 CEA对肺癌诊断 已有较高的特异性, 但如加上 NSE、 唾液酸、 CEA、 SCC则特异性更高。
本发明所述用于多指标并行检测的蛋白芯片的另一个优点是灵敏 度高, 利用化学发光反应和增强发光反应使得本蛋白芯片可检测每毫 升体液中含量仅有 lpg的目标蛋白质, 这使得一些特异性高但在体液 中含量很低的蛋白质指柄可以被用于临床检测, 从而扩大了临床检测 指标的选择范围。
蛋白芯片以其特有的优势可为现代医学诊断学提供高效、 便捷、 准确的临床检测手段, 对疑难病症的确诊及恶性疾病(如肿瘤)的早期 诊断和及时治疗有重大的意义。 由于蛋白质比基因更进一步的接近生 命活动的物质层面, 因此蛋白芯片在疾病诊断和治疗, 新型药物开发, 探索疾病的分子机理等生命科学相关领域有着比基因芯片更加直接的 应用前景。
以下医用体外诊断试剂的技术指标中, 本发明蛋白芯片检测系统 的达标情况为 :
灵敏度: 真阳性 /(真阳性 +假阴性) > 80% ;
检测下限对血清样品为 10— 12克 /亳升。
特异性: 真阴性 /(真阴性 +假阳性) > 95%。
稳定性: 4 °C可稳定放置 2年; 37 °C可稳定放置 1周。
简便性: 1 .5小时内完成实验。
安全性: 无放射性, 无污染. 附图的简要说明
图 1是用本发明蛋白芯片检测的标准血样结果的示意图; 图 2是用本发明蛋白芯片检测的肝癌患者血样结果的示意图。 实现本发明的最佳方式
下面以具体实施例进一步阐述本发明,但并不限制本发明的范围。 实施例 1 蛋白芯片的制备
固相载体: 硝酸纤维素膜。
固相载体上所用蛋白质 : 检测肿瘤标志性蛋白的单克隆抗体, 所 用量为 5 ng, 点样密度为 25点 /0.36cm2
点样物为 Al, A2— CA153抗体, A3, A4— CA19- 9抗体, A5—负对 照, Bl, B2— CA125抗体, B3, C4— AFF抗体, CI, C2— CA125抗体, C3, B4— beta-HCG抗体, B5, C5— CA19-5抗体, Dl , D2— PSA抗体, D3, E4— CEA抗体, El, E2— PSA抗体, E3, D4— CA15-3抗体, D5, E5— CA549抗体。
抗体购自 Fitzgerald, CanAg。
AFP—甲胎蛋白, CEA—癌胚抗原, PSA—前列腺特畀性抗原, betaHCG—人绒毛膜促性腺激素 beta亚基, CA—统称糖类抗原, 负对 照一不加任何点样物。
包被液: pH 9.6的 CBS (NaHC03-Na2C03)。
封闭液: 0.9 NaCl . 1.21%Tris、 0.2%Tween 20. 0.1%酪氨酸、 4% 蔗糖、 5%BSA、 0.5%proclin。
制备步骤:
1) 将蛋白芯片上所要点制的蛋白质溶于包被液中浓度为 25%, 然 后用芯片 自动点样系统 (BioGrid Total Array Systen, BioRobotics 公司)将这些蛋白质点制在固相载体上。
2) 放置过夜。
3) 用封闭液将蛋白芯片封闭冻干处理, 储存于 4 (:。
实施例 2 蛋白的检测 正常人血样 (附图 1 ) 和肝癌患者血样 (附图 2) 用本发明蛋白芯 片检测的结果比较。
正常人血样和肝癌病人血样均来自上海市第八人民医院肿瘤科。 所用的蛋白芯片的点样位置如上芯片的制备:
操作步骤:
1 ) 用稀释液将待测的血清上清液稀释 5倍。
2)吸取稀释液, 按照每平方厘米蛋白芯片 500 μ ΐ 的体积滴加到 蛋白芯片表面, 在 300转 /分钟的频率和 37 C下振摇 25分钟, 使体 液中的肿瘤标志性蛋白与固定于蛋白芯片上的单抗起反应,形成抗原- 抗体复合物。
3 )吸干反应液, 将蛋白芯片放在洗涤液中振摇洗涤 4分钟, 重复 三次。
4) 吸取已标记辣根过氧化物酶的 多种单抗混合液 (购 自 Fitzgerald , CanAg 公司) , 这些单抗是和上述指标对应的另一种抗 体的混合物。 按照每平方厘米蛋白芯片约 500 μ 1 的体积滴加到蛋白 芯片表面, 在 300转 /分钟的频率和 37 C下振摇 25分钟, 抗原抗体 复合物与多种单抗混合液中的另一单抗结合, 形成稳定的三聚物: 抗 体-抗原-另一单抗 (标 HRF) 复合物。
5 )吸干反应液, 将蛋白芯片放在洗涤液中振摇洗涤 4分钟, 重复 三次。
6)在晾千后的芯片表面滴加产生化学发光反应的化学組合物(100 μ 1/cm2) , 37 C催化反应 3分钟。化学組合物: Luminol ( 5- amino-2 , 3-dihydro-l , 4-phthalazinedione Sodium Salt ) > H202(过氧化氪), 增强子 Enhancer , 辣根过氧化物酶 (HRP), 均购自 Sigma公司 。
7 ) 取出芯片 , 10 分钟时检测光信号。 使光信号通过透镜成像, 再将光信号转变为数字信号, 用软件进行定量分析, 可检测到的最小 信号换算成蛋白量是 10— 12克量級。 结果如图所示, 在(A3 , A4)和(B3 , C4)位置处肝癌病人的血样检 测结果与正常人血样的检测结果有强烈的信号差异, 在此位置对应检 測的月中瘤标志物为 CA19-9和 AFP。 工业应用性
本发明的优点和应用前景是十分明显的。 使用本发明所述的蛋 白芯片使得检测的准确性极大提高, 并具有可靠性高、 检测灵敏度 高等优点, 可广泛应用于分子生物学、 生物医学、人类蛋白质組研究, 尤其应用于临床诊断。

Claims

杈利要求
1 . 一种蛋白芯片 ,
其特征在于, 它由固相载体和固定于载体上用于多指标并行检测的蛋 白。
2 . 根据杈利要求 1的蛋白芯片 ,
其特征在于, 所述的蛋白指抗原、 抗体、 受体、 配体。
3 . 根据杈利要求 2的蛋白芯片 ,
其特征在于, 所述的蛋白指与疾病标志性蛋白特异性结合的蛋白 。
4 . 根据杈利要求 3的蛋白芯片 ,
其特征在于, 所述的蛋白指能与体内肿瘤标志物特异性结合的蛋白。
5 . 根据杈利要求 1的蛋白芯片 ,
其特征在于, 所述的固相载体指无机片基或有机化合物片基。
6 . 根据杈利要求 5的蛋白芯片 ,
其特征在于, 所述的固相载体指是醋酸纤维素膜、 硝酸纤维素膜、 尼 龙膜或聚丙烯膜。
7 - 根据杈利要求 5的蛋白芯片 ,
其特征在于, 所述的固相载体指半导体硅片 、 玻璃片 、 微孔硅片或徵 孔玻璃。
8 . 根据杈利要求 1的蛋白芯片 ,
其特征在于, 所述的蛋白质的分布密度不低于 25 dot/cm2。
9 . 根据杈利要求 1的蛋白芯片 ,
其特征在于, 所述的蛋白质的量是 0 . 1 ng/dot至 10 ng/dot范围内。
10 . —种蛋白芯片的制备方法,
其特征在于,
(a)在固相载体上以一定的排列次序固定多种蛋白质;
( b)然后用封闭液将固相载体的非点样部位封闭, 冻干保存。
11. 根据杈利要求 10的制备方法,
其特征在于, 所述的蛋白质是以共价结合或物理吸附的原理固定到固 相载体表面的。
12- 根据杈利要求 10的制备方法,
其特征在于, 所述的封闭液含有蔗糖、 BSA、 Tween 20、 PBS, 酪氨酸。
13. 根据杈利要求 12的制备方法,
其特征在于, 所述的封闭液含有 0.1- 0.5%Tween 20、 0.02- 0.3%酪氨 酸、 1-9¾蔗糖、 1-9%BSA、 0.1-l%proclin
14. 根据杈利要求 12的制备方法,
其特征在于, 所述的封闭液含有 0.2%Tween20、 0.1%酪氨酸、 4%蔗糖、 5¾BSA 0.5%proclin。
15. 根据杈利要求 11的制备方法,
其特征在于, 蛋白质先溶于包被液, 包被液为: pH 为 9.0-10.0 的 NaHC03-Na2C03緩沖液。
16- 一种用于多指标并行检测的蛋白芯片检测系统,
其特征在于, 它利用化学发光反应同时检测多种生物大分子在体液内 的含量, 该检测系统包括:
(1)一种用于多指标并行检测的蛋白芯片 ;
(2)—种标记过氧化物酶的多蛋白质混合液;
(3)—种用于稀释被测体液的稀释液;
(4)一种由产生并增强化学发光反应的化合物组成的化学组合物;
(5)—种蛋白芯片的洗涤液;
(6)—系列被检蛋白质的标准品。
17- 杈利要求 16所述的检测系统,
其特征在于, 所述的过氧化物酶是辣根过氧化物酶。
18. 杈利要求 16所述的检测系统 ,
其特征在于, 所述的多蛋白质混合液是可与在体液中被检测到的蛋白 质特异性结合的多种标记过氧化物酶的蛋白质, 以一定浓度配比后的 混合液。
19. 根据杈利要求 16所述的检测系统,
其特征在于, 所述的洗涤液内含 0.7- 0.9%NaCl, 1.0-1.5% Tris , 0.05-0.2%Tween 20, pH值在 6.0至 9.0之间 。
20. 根据杈利要求 19所述的检测系统,
其特征在于, 所述的洗涤液优选配方为 0.9%NaCl, 1.21% Tris, 0.1 Tween 20, pH值为 7.50。
21. 根据杈利要求 16所述的检测系统,
其特征在于, 所述的稀释液内含 0.7-0.9%NaCl, 1.0-1.5% Tris , 0.05-0.2%Tween 20, 0.05-0.2%酪氨酸。
22. 根据杈利要求 21所述的检测系统,
其特征在于, 所述的稀释液优选配方为 0.9%NaCl, 1.21% Tris, 0.1%Tween 20, 0.1%酪氨酸。
23. 一种利用杈利要求 16所述的检测系统进行检测的方法, 其特征在于, 它包括如下步骤:
(1) 将结合了多个可与体内指标特异性结合的蛋白 (B) 的固相载 体与含目椋蛋白 (A) 的待测液接触, 并使其充分反应形成稳定复合物
(B - A) ;
(2) 复合物 (B- A) 进一步与多蛋白混合液中对应标记 (A) 的特 异结合蛋白(C-labelled)反应,形成稳定复合物(B -A-C-labelled), 标记是化学发光法的柘记物;
(3) 加上产生化学发光反应的化学組合物, 使反应发光;
(4) 信号检测。
24. 根据杈利要求 23的方法,
其特征在于, 所述的标记物是过氧化物酶。
25. 根据杈利要求 23的方法, 其特征在于, 所述的多蛋白混合液是可与在体液中被检测到的蛋白质 特异性结合的多种标记过氧化物酶的蛋白质, 以一定浓度配比后的混 合液。
26 . 根据杈利要求 24或 25的方法,
其特征在于, 所述的过氧化物酶是辣根过氧化物酶。
PCT/CN2001/001294 2001-01-04 2001-08-30 Puces proteiques, leur procede de production, leur systeme de detection et le procede de mise en route du systeme de detection WO2002054070A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002428428A CA2428428A1 (en) 2001-01-04 2001-08-30 Protein chips, method producing it and detection system of the protein chips, and operating method of the detection system
EP01982082A EP1348961A4 (en) 2001-01-04 2001-08-30 PROTEIN CHIPS, METHOD OF MANUFACTURING THEREOF, AND PROBLEM SYSTEM FOR PROTEIN CHIPS AND OPERATING PROCESS FOR THE SEALING SYSTEM
JP2002554717A JP2004516489A (ja) 2001-01-04 2001-08-30 蛋白チップ、その作製方法、該蛋白チップを使用する検出システムおよび該検出システムを使用する方法
US10/464,127 US20030228631A1 (en) 2001-01-04 2003-06-18 Protein chips, method producing it and detection system of the protein chips, and operating method of the detection system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN01105023.3 2001-01-04
CN01105023.3A CN1217194C (zh) 2001-01-04 2001-01-04 蛋白芯片及其制备方法和使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/464,127 Continuation US20030228631A1 (en) 2001-01-04 2003-06-18 Protein chips, method producing it and detection system of the protein chips, and operating method of the detection system

Publications (1)

Publication Number Publication Date
WO2002054070A1 true WO2002054070A1 (fr) 2002-07-11

Family

ID=4654111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001294 WO2002054070A1 (fr) 2001-01-04 2001-08-30 Puces proteiques, leur procede de production, leur systeme de detection et le procede de mise en route du systeme de detection

Country Status (6)

Country Link
US (1) US20030228631A1 (zh)
EP (1) EP1348961A4 (zh)
JP (1) JP2004516489A (zh)
CN (1) CN1217194C (zh)
CA (1) CA2428428A1 (zh)
WO (1) WO2002054070A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033307A1 (ja) * 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
EP1560023A1 (en) * 2002-10-24 2005-08-03 Shanghai Health Digit Co. Limited A protein chips detecting system which can simultaneously detect multi target
US7442773B2 (en) 2004-01-23 2008-10-28 The Board Of Trustees Of The University Of Illinois Universal peptide-binding scaffolds and protein chips

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164948C (zh) * 2002-06-06 2004-09-01 成都夸常科技有限公司 一种基于抗原抗体反应的试剂盒
CN100504395C (zh) * 2003-07-18 2009-06-24 上海数康生物科技有限公司 Sars病毒诊断试剂
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
JP4862412B2 (ja) * 2006-01-31 2012-01-25 住友ベークライト株式会社 バイオチップの製造方法
US20080200342A1 (en) 2007-02-15 2008-08-21 Rao Rupa S Device, Array, And Methods For Disease Detection And Analysis
WO2008122241A1 (en) * 2007-04-04 2008-10-16 Diagcor Bioscience Incorporation Limited Rapid protein analyses and the device thereof
CN101126759B (zh) * 2007-09-21 2011-05-11 王琳 塑料试管蛋白芯片、其制备方法及应用
CN101477117B (zh) * 2009-01-16 2012-12-19 中国农业科学院哈尔滨兽医研究所 检测禽病血清抗体的可视化蛋白芯片及其制备方法和应用
CN102175860A (zh) * 2010-12-15 2011-09-07 中国疾病预防控制中心寄生虫病预防控制所 一种检测寄生虫病的蛋白芯片及其试剂盒和制备方法
CN102141569A (zh) * 2010-12-15 2011-08-03 中国疾病预防控制中心寄生虫病预防控制所 一种用于联合诊断三种吸虫病的蛋白芯片及其制备方法
CN102621301B (zh) * 2011-01-28 2014-10-08 上海铭源数康生物芯片有限公司 一种基于硝酸纤维素膜的蛋白芯片封闭液的制备方法
CN102676640B (zh) * 2011-03-10 2014-11-26 国家纳米科学中心 催化复合物及可视化检测方法
CN102830233B (zh) * 2011-06-13 2015-08-26 上海铭源数康生物芯片有限公司 一种基于硝酸纤维素膜的elisa反应方法
CN102621330A (zh) * 2012-04-05 2012-08-01 中国疾病预防控制中心营养与食品安全所 用于检测人体铁储量的蛋白芯片及其试剂盒
CN102645530B (zh) * 2012-04-06 2014-06-18 上海蓝怡科技有限公司 甲状腺素酶联免疫体外诊断试剂盒中酶结合物稀释液的制备方法
EP3159695A3 (en) * 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Methods for diagnosing pancreatic cancer
CN107782721A (zh) * 2016-08-26 2018-03-09 韦彦余 一种基于膜的生物样品化学发光检测方法和相关检测试剂盒
CN107238703A (zh) * 2017-07-19 2017-10-10 陈剑桃 一种可检测6种养殖鱼类细菌性疾病的抗体芯片
CN108593939B (zh) * 2018-07-18 2023-11-14 瑞博奥(广州)生物科技股份有限公司 一种全自动蛋白芯片及其应用
CN111239412A (zh) * 2020-01-20 2020-06-05 复旦大学附属中山医院 聚焦肝细胞肝癌的蛋白小芯片的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015834A1 (en) * 1996-10-07 1998-04-16 Schering Corporation ASSAY FOR THE DETECTION OF ANTIBODIES AGAINST p53
US5874219A (en) * 1995-06-07 1999-02-23 Affymetrix, Inc. Methods for concurrently processing multiple biological chip assays
EP1041385A2 (en) * 1999-03-30 2000-10-04 Fuji Photo Film Co., Ltd. Method and apparatus for detecting an organism-originated substance
CN1274085A (zh) * 2000-04-13 2000-11-22 陈学银 一种蛋白芯片及其制备方法并用其筛选单克隆抗体
CN1274758A (zh) * 1999-05-21 2000-11-29 陆祖宏 制备化合物微阵列芯片的方法及由该方法制备的化合物微阵列芯片

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089423A (en) * 1987-05-06 1992-02-18 Cyberfluor Inc. Immunoassay methods and reagents and methods for producing the latter
IL99630A0 (en) * 1991-10-02 1992-08-18 Channa Shalitin Novel antibodies useful for the detection of benign and malignant tumors
US5610021A (en) * 1992-02-21 1997-03-11 Creative Biomolecules, Inc. Compositions and methods for identification and use of soluble complex forms of osteogenic proteins
US5494829A (en) * 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5922533A (en) * 1997-08-15 1999-07-13 Abbott Laboratories Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
US6531305B1 (en) * 1998-09-10 2003-03-11 University Of Massachusetts Sperm associated protein kinase polypeptides, corresponding nucleic acids, and methods of use
WO2000058726A1 (fr) * 1999-03-29 2000-10-05 Asahi Kasei Kabushiki Kaisha Procede de numeration des leucocytes dans un echantillon de sang complet
KR20000071894A (ko) * 1999-08-19 2000-12-05 김선영 단백질칩 및 이를 이용한 다목적 자동화 진단시스템
US6855538B2 (en) * 2001-06-27 2005-02-15 The Regents Of The University Of California High-efficiency microarray printing device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874219A (en) * 1995-06-07 1999-02-23 Affymetrix, Inc. Methods for concurrently processing multiple biological chip assays
WO1998015834A1 (en) * 1996-10-07 1998-04-16 Schering Corporation ASSAY FOR THE DETECTION OF ANTIBODIES AGAINST p53
EP1041385A2 (en) * 1999-03-30 2000-10-04 Fuji Photo Film Co., Ltd. Method and apparatus for detecting an organism-originated substance
CN1274758A (zh) * 1999-05-21 2000-11-29 陆祖宏 制备化合物微阵列芯片的方法及由该方法制备的化合物微阵列芯片
CN1274085A (zh) * 2000-04-13 2000-11-22 陈学银 一种蛋白芯片及其制备方法并用其筛选单克隆抗体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560023A1 (en) * 2002-10-24 2005-08-03 Shanghai Health Digit Co. Limited A protein chips detecting system which can simultaneously detect multi target
EP1560023A4 (en) * 2002-10-24 2007-08-01 Shanghai Health Digit Co Ltd PROTEIN CHIP DETECTION SYSTEM WHICH CAN DETECT A MULTIPLE TARGET AT THE SAME TIME
WO2005033307A1 (ja) * 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
US7442773B2 (en) 2004-01-23 2008-10-28 The Board Of Trustees Of The University Of Illinois Universal peptide-binding scaffolds and protein chips

Also Published As

Publication number Publication date
CA2428428A1 (en) 2002-07-11
CN1217194C (zh) 2005-08-31
CN1363840A (zh) 2002-08-14
EP1348961A1 (en) 2003-10-01
EP1348961A4 (en) 2006-06-28
US20030228631A1 (en) 2003-12-11
JP2004516489A (ja) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2002054070A1 (fr) Puces proteiques, leur procede de production, leur systeme de detection et le procede de mise en route du systeme de detection
CN100386627C (zh) 过滤型蛋白芯片
JP2020126068A (ja) コバインダー補助アッセイ法
US8530230B2 (en) Multiplexed assay methods
JP4222756B2 (ja) 固相生体分子分析調製同定システム用コロイド組成物
CN102721813A (zh) 前列腺特异抗原均相发光免疫分析检测试剂盒及其检测方法
RU2298796C2 (ru) Диагностическая система, содержащая белковые чипы и выполненная с возможностью одновременного определения множества показателей
JP2005504988A (ja) 較正マイクロアレイ
EP4119945A1 (en) Highly sensitive immunoconjugate, preparing method thereof, in vitro diagnostic reagent and in vitro diagnostic kit including the same
CN1865994B (zh) 含有机分子交联标记的分析方法及与之相关的分析组成
JP4230126B2 (ja) 生物学的素材チップ
RU2682721C2 (ru) Биологический микрочип для обнаружения опухолевых экзосом в сыворотке крови человека для диагностики колоректального рака
JP4207754B2 (ja) 磁性体を用いた免疫学的測定方法
CN210894379U (zh) 一种基于微流控芯片的抗体检测系统
US20070037174A1 (en) Chemiluminescent generated fluorescent labeling
CN101126759B (zh) 塑料试管蛋白芯片、其制备方法及应用
Ito Microarray Chips (in Vitro Diagnosis)
CN113945713A (zh) 用于多种肿瘤标志物联合检测的生物芯片及其制备与应用
CN117388499A (zh) 血清中抗原类蛋白的化学发光蛋白芯片方法和试剂盒
TW201131158A (en) Biochemical detection unit and biochemical device having the same
Ricchiuti IMMUNOASSAY-BASED TECHNOL-OGIES F OR THE MEASUREMENT OF BIOLOGICAL MATERIALS USED FOR BIOMARKERS DISCOVERY AND TRANSLATIONAL RESEARCH
CN116445592A (zh) 一种改进的elisa测试方法
JP2021525376A (ja) 化学発光免疫分析測定法及び該方法を使用するシステム、試薬キット
EP3387154A1 (en) Automated silver enhancement system
JP2005283351A (ja) 蛋白質固定化方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2428428

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10464127

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002554717

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001982082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001982082

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001982082

Country of ref document: EP